by Mark Curtis | Apr 25, 2016
Welcome to your Cell Therapy Deal Review for the month of March. Cellectis continues to differentiate through a collaboration with MabQuest. PCT formed a partnership with Japanese conglomerate Hitachi. Kite partnered with Roche’s Genentech on a program for lymphoma....
by Stacey Johnson | Apr 15, 2016
The picture to the right is of my cat Chloe, all dressed up for her debut on Signals. Amazingly, Franklin West (University of Georgia) thinks domesticated cats (Chloe!) are the ideal vessel for saving big cats of the endangered species kind. The idea is to collect...
by Mark Curtis | Mar 24, 2016
Welcome to your Update from the Clinic for the month of February. bluebird made its debut in the oncology market and treated its first patient with a chimeric antigen receptor (CAR) product targeting a novel antigen. Ziopharm enrolled its first patient in a study...
by Mark Curtis | Mar 15, 2016
Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto,...
by Stacey Johnson | Mar 11, 2016
Tissue engineering is a key part of regenerative medicine (RM), but it sometimes feels like the poor cousin of stem cells. The Jan to big sister Marcia. That won’t be the case at the upcoming 10th World Biomaterials Congress (WBC2016), happening May 17-22 in Montreal,...
by James Smith | Mar 7, 2016
Post by James Smith and Mackenna Roberts. Ms. Roberts is an English-qualified lawyer, trained bioethicist and strategic adviser for the commercialization of emerging biomedical technologies and is widely published on how the law should govern cutting-edge medical...
Comments